Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

498
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
498
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

574
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
574
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

705
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
705
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

611
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
611
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

459
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
459
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

296
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
296

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antioxidant and Geno-protective Effects of Naturally Occurring Delphinidin Glycosides.

Mutagenesis·2026
Same author

Reply - Letter to the Editor: Clinical and Immunologic Effects of Extracorporeal Cytokine Removal in Patients with Septic Shock: A Randomized Controlled Trial.

Shock (Augusta, Ga.)·2026
Same author

Reply - Letters to the Editor by Hübner, Berlot, Bottari et al.: Clinical and Immunologic Effects of Extracorporeal Cytokine Removal in Patients with Septic Shock: A Randomized Controlled Trial.

Shock (Augusta, Ga.)·2026
Same author

Clinical and Immunologic Effects of Extracorporeal Cytokine Removal in Patients with Septic Shock: A Randomized Controlled Trial.

Shock (Augusta, Ga.)·2026
Same author

Surgical Pulmonary Embolectomy Versus Systemic Thrombolysis in High-Risk Pulmonary Embolism: A Retrospective Single-Center Analysis.

Journal of clinical medicine·2025
Same author

Tidal volume and mortality during extracorporeal membrane oxygenation for acute respiratory distress syndrome: a multicenter observational cohort study.

Annals of intensive care·2025

Related Experiment Video

Updated: Mar 15, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.2K

[Cardiac support and replacement therapies].

Christopher Lotz1, Norbert Roewer1, Ralf M Muellenbach1

  • 1Klinik und Poliklinik für Anästhesiologie, Universitätsklinikum Würzburg.

Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS
|September 16, 2016
PubMed
Summary

Pharmacologic therapies and mechanical circulatory support (MCS) aid critically ill patients with low cardiac output. While MCS like venoarterial extracorporeal membrane oxygenation (vaECMO) can improve outcomes, survival benefits for pharmacologic regimens remain unproven.

More Related Videos

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

3.3K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.1K

Related Experiment Videos

Last Updated: Mar 15, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.2K
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

3.3K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.1K

Area of Science:

  • Critical Care Medicine
  • Cardiology
  • Cardiovascular Pharmacology

Background:

  • Circulatory support is vital for critically ill patients.
  • Pharmacologic agents like catecholamines, PDE-III inhibitors, and levosimendan aim to improve systemic perfusion.
  • Mechanical circulatory support (MCS) is an option when pharmacologic measures are insufficient.

Purpose of the Study:

  • To review the role of pharmacologic and mechanical circulatory support in managing critically ill patients.
  • To highlight levosimendan as a potential treatment for low cardiac output.
  • To discuss the application of MCS, including vaECMO, in critical care scenarios.

Main Methods:

  • Literature review of pharmacologic and mechanical circulatory support strategies.
  • Analysis of current evidence for drug efficacy and MCS in critical care.
  • Discussion of indications and outcomes for MCS, particularly vaECMO.

Main Results:

  • Pharmacologic regimens can enhance vascular tone and inotropic effects but lack proven survival benefits.
  • Mechanical circulatory support (MCS) is utilized for cardiopulmonary resuscitation and low-cardiac-output syndrome.
  • Venoarterial extracorporeal membrane oxygenation (vaECMO) can support cardiopulmonary function and potentially improve survival and neurological outcomes.

Conclusions:

  • No pharmacologic regimen has demonstrated a definitive survival benefit in critically ill patients.
  • MCS, including vaECMO, serves as a crucial bridge or support during critical events like cardiogenic shock or resuscitation.
  • Further research is needed to establish survival benefits for specific pharmacologic treatments.